Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

MOLECULAR DETERMINANTS OF RESPONSE TO ANTIANGIOGENIC THERAPIES IN PRECLINICAL MODELS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA

Gyanchandani, Rekha (2013) MOLECULAR DETERMINANTS OF RESPONSE TO ANTIANGIOGENIC THERAPIES IN PRECLINICAL MODELS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA. Doctoral Dissertation, University of Pittsburgh. (Unpublished)

[img]
Preview
PDF (Gyanchandani Rekha PhD Dissertation 2013)
Submitted Version

Download (11MB) | Preview

Abstract

Abstract
Background
Head and neck squamous cell carcinoma (HNSCC) is the eighth leading cancer by incidence worldwide. In the past 5 decades there have been significant advances in surgery and chemoradiotherapy, but very little improvement in survival rates. Hence, there is a pressing need to develop new therapeutic strategies in HNSCC. Antiangiogenic therapy represents a promising strategy in at least a subset of patients. Currently, there are no reliable predictive and resistance biomarkers to identify those patients most likely to benefit. Studies using relevant preclinical models that identify mechanisms of resistance to antiangiogenic agents will help meet these challenges.
Principal Findings
In this dissertation, we established preclinical models of intrinsic and acquired resistance to anti-VEGF antibody bevacizumab and identified potential biomarkers of drug response.
To characterize mechanisms of intrinsic resistance, we evaluated the angiogenic profile of HNSCC cells from bevacizumab-sensitive and -resistant tumor models using antibody array. We showed that resistant cells expressed higher levels of proangiogenic factors including interleukin-8 (IL-8). We identified PI3K and IL-1α signaling as the molecular basis for overexpression of IL-8. Downregulation of IL-8 resulted in sensitization of resistant tumors to bevacizumab. Overexpression of IL-8 in sensitive tumors conferred resistance to bevacizumab. Serum analysis of HNSCC patients treated with a bevacizumab-containing regime indicated high baseline IL-8 levels in a subset of patients refractory to treatment but not in responders.
In a novel xenograft model of acquired resistance, human-specific microarray analysis revealed upregulation of angiogenesis-related genes including fibroblast growth factor-2 (FGF2), fibroblast growth factor receptor-3 (FGFR3), phospholipase C gamma-2 (PLCg2), frizzled receptor-4 (FZD4), chemokine [C-X3-C motif] ligand-1 (CX3CL1), and chemokine [C-C motif] ligand-5 (CCL5). Upstream genes PLCg2, FZD4, CX3CL1, and CCL5 regulated increased expression of FGF2 via increased extracellular signal-regulated kinase (ERK) signaling. Co-targeting VEGF and FGFR sensitized resistant tumors to bevacizumab.
Conclusions and Significance
Our work has identified two distinct molecular mechanisms of resistance to bevacizumab in preclinical HNSCC models. IL-8 signaling mediated intrinsic resistance while upregulation of FGF signaling in response to anti-VEGF therapy contributed to acquired resistance. Above findings provide a mechanistic rationale for co-targeting these pathways in future clinical trials to enhance the therapeutic efficacy of antiangiogenic therapy.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: University of Pittsburgh ETD
Status: Unpublished
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Gyanchandani, Rekhareg31@pitt.eduREG31
ETD Committee:
TitleMemberEmail AddressPitt UsernameORCID
Thesis AdvisorKim, Seungwonkimsw2@upmc.eduSWK7
Committee ChairZhang, Linzhanglx@upmc.eduLIZ22
Committee MemberGrandis, Jennifergrandisjr@upmc.edu
Committee MemberWang, Zhouwangz2@upmc.eduWANGZ2
Committee MemberMonga, Satdarshan P. S.smonga@pitt.eduSMONGA
Date: 30 April 2013
Date Type: Publication
Defense Date: 12 April 2013
Approval Date: 30 April 2013
Submission Date: 30 April 2013
Access Restriction: 2 year -- Restrict access to University of Pittsburgh for a period of 2 years.
Number of Pages: 113
Institution: University of Pittsburgh
Schools and Programs: School of Medicine > Pharmacology and Chemical Biology
Degree: PhD - Doctor of Philosophy
Thesis Type: Doctoral Dissertation
Refereed: Yes
Uncontrolled Keywords: Angiogenesis, Acquired resistance, Bevacizumab, Biomarker, FGF, HNSCC, Intrinsic resistance, IL-8.
Date Deposited: 30 Apr 2013 12:53
Last Modified: 19 Dec 2016 14:40
URI: http://d-scholarship.pitt.edu/id/eprint/17327

Metrics

Monthly Views for the past 3 years

Plum Analytics


Actions (login required)

View Item View Item